Application for PRECISEU Best Practice Recognition – Your Excellence Deserves Recognition!

Application for PRECISEU Best Practice Recognition – Your Excellence Deserves Recognition!
Go back

Apply now for the second Edition of the PRECISEU Best Practice Recognition!

The PRECISEU Best Practice Recognition is more than a contest—it is a movement to accelerate the future of personalised medicine across Europe. Born from the PeRsonalised medicine Empowerment Connecting Innovation ecoSystems across EUrope (PRECISEU) programme, this visionary initiative shines a spotlight on pioneers who are translating cutting-edge science into realworld care—especially through the innovative and responsible use of health data. With ambitious purpose it celebrates exemplary practices that not only push the boundaries of what’s possible but also make these breakthroughs accessible, equitable, and impactful for all. This recognition is a catalyst for transformation—bridging science and society, innovation and implementation, vision and care. It calls upon researchers, entrepreneurs, institutions, and citizens alike to lead with purpose, collaborate boldly, and ensure that life-changing therapies reach every patient, everywhere—fast and fair. PRECISEU Best Practice Recognition honours not just innovation, but the courage to act, the will to include, and the power to change lives.

The call is now open for the second Edition

We offer three more sessions where we explain how to apply:

Info session 1: 12 December 2025, 1:30 – 2:30 pm – register here

Info session 2: 8 January 2026  1:30 – 2:30 pm – register here

Info session 3: 6. February 2026, 1:30 – 2:30 pm – register here

Find a preview to the questionnaire to be filed here. 

Call deadline March 1st 2026. Apply here. 

 Useful links

register now

Our latest News

discover more
A single swab is sufficient: Study paves the way for simplified tuberculosis diagnosis

A single swab is sufficient: Study paves the way for simplified tuberculosis diagnosis

Led by researchers from Heidelberg Faculty of Medicine at Heidelberg University and the University of California, San Francisco (USA), an international research team has evaluated a novel approach for the diagnosis of pulmonary tuberculosis. The method enables detection of Mycobacterium tuberculosis without laboratory infrastructure, within a markedly shorter time frame than conventional diagnostics, and using […]

read more
Hella Bühler Prize Awarded to DKFZ Researcher Angelika Feldmann

Hella Bühler Prize Awarded to DKFZ Researcher Angelika Feldmann

For her groundbreaking research on the regulation of gene activity, Angelika Feldmann has been awarded the 2026 Hella Bühler Prize, which comes with a grant of €100,000. Presented by Heidelberg University, the award is intended for young researchers in the Heidelberg research community who have already distinguished themselves through outstanding scientific achievements in cancer research. […]

read more
New Nature Publication by Akribion Therapeutics GmbH: RNA-triggered cell killing with CRISPR–Cas12a2

New Nature Publication by Akribion Therapeutics GmbH: RNA-triggered cell killing with CRISPR–Cas12a2

Scholz, P., Thompson, J., Crosby, K.T. et al. RNA-triggered cell killing with CRISPR–Cas12a2. Nature (2026). https://doi.org/10.1038/s41586-026-10466-y Abstract Selectively eradicating target cells on the basis of their genetic or transcriptional identity remains important in basic research, medicine, biotechnology and agriculture1,2,3. For applications involving bacteria, CRISPR nucleases offer promising options due to their ability to enact RNA-guided counterselection4,5,6,7; however, using these […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp